

Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program

September 20, 2018

Effective **September 27, 2018**, Renflexis (infliximab) will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients.

Renflexis will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for the following indications:

- Crohn's Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis

Details of the LU criteria will also be posted in the September 2018 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.